Aldeyra Therapeutics Stock Is Trading Higher On Acing Allergic Conjunctivitis Study With Reproxalap

This post was originally published on this site

  • Aldeyra Therapeutics Inc (NASDAQ: ALDX) has announced positive top-line results from the Phase 3 INVIGORATE trial evaluating 0.25% reproxalap, in patients with allergic conjunctivitis.
  • The 95-subject trial achieved statistical significance for the primary endpoint and all secondary endpoints.
  • The primary efficacy endpoint was the change from baseline in subject-reported ocular itching score after allergen chamber entry. The key secondary endpoint was the change from baseline in ocular redness over the duration of the allergen chamber (approximately 3.5 hours).
  • Relative to patients treated with vehicle, patients treated with reproxalap reported statistically significant ocular itching score reduction across all 11 prespecified primary endpoint comparisons (p<0.0001 for each comparison).
  • The reproxalap-treated patients demonstrated a statistically significant reduction in ocular redness over the duration of the allergen chamber.
  • The company is also conducting TRANQUILITY trials in dry eye disease, with data expected in the second half of 2021.
  • Aldeyra plans to meet with the FDA in the second half of 2021 to discuss the INVIGORATE results and the potential submission of a marketing application.
  • Reproxalap is a novel small-molecule immune-modulating covalent inhibitor of RASP elevated in ocular and systemic inflammatory disease.
  • The company will host a conference call at 8:00 a.m. ET today.
  • Price Action: ALDX shares are up 31.9% at $14.65 in premarket trading on the last check Tuesday.
SUBSCRIBE NOW:







Aldeyra Therapeutics NewsMORE

“;
}
}
tableString += “”;
}
tableString += “”;
}
}
tableString += “”;
$(‘#detail-news-table’).html(tableString);

try { trackPI(); } catch (e) { }
};

function insertNewsHelp() {
var help = “To give you an overview of the large number of messages that appear every day for a company, we have broken the news feed in the following categories:u003cbr/u003eRelevant : News from selected sources that deal specifically with this company u003cbr/u003eAll: All news about this company. u003cbr/u003eCompany News: News issued by the company directly.”;
$(‘#detail-news-table’).html(help);
try { trackPI(); } catch (e) { }
};

Related Posts